clinical trial · NCT07392060
A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
Shanghai Jiatan Pharmatech Co., Ltd·phase3·not yet recruiting·n = 440
Cervical Cancer MetastaticWX390 1.1mg + Toripalimab 240mgInvestigator's Choice of Chemotherapy
brief summary
This is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior platinum-based systemic therapy, as assessed by overall survival (OS).
started
Feb 28, 2026
primary completion
Sep 30, 2029
completion
Jun 30, 2030
last updated
Feb 6, 2026
official title
A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol